Patent application number | Description | Published |
20080206243 | Methods for Treating Kidney Disorders - Provided are methods of treating kidney disorders in a subject by administering an effective amount of VEGFR agonist, e.g., a Flt1 agonist to a subject. The agonists are composed of compositions comprising VEGFR agonists, e.g., VEGF, antibodies directed to Flt1, Flt1 ligands, Flt1 small molecule activators, or Flt1 selective agents in a pharmaceutically acceptable carrier for use in activating Flt1. | 08-28-2008 |
20090136526 | CD19 Binding Agents and Uses Thereof - This invention, inter alia, relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease. | 05-28-2009 |
20100189719 | ANTI-VEGF ANTIBODIES - Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications. | 07-29-2010 |
20100239568 | DIAGNOSTICS AND TREATMENTS FOR TUMORS - Methods for the treatment of cancer with combination therapies that include anti-VEGF antibodies are provided. Methods for diagnosing resistant tumors are also provided. | 09-23-2010 |
20110014198 | ANTI-VEGF ANTIBODIES - Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications. | 01-20-2011 |
20110020346 | ANTI-VEGF ANTIBODIES - Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications. | 01-27-2011 |
20110312088 | CD19 BINDING AGENTS AND USES THEREOF - This invention, inter alia, relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease. | 12-22-2011 |
20120294853 | CD19 Binding Agents and Uses Thereof - This invention, inter alia, relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease. | 11-22-2012 |
20120322982 | ANTI-VEGF ANTIBODIES - Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications. | 12-20-2012 |
20130266581 | ANTI-VEGF ANTIBODIES - Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications. | 10-10-2013 |
20130315918 | ANTI-VEGF ANTIBODIES - Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications. | 11-28-2013 |